Acute fatal amiodarone-induced lung toxicity after CABG surgery  by Panagiotou, Ioannis et al.
lable at ScienceDirect
Respiratory Medicine CME 4 (2011) 37e39Contents lists avaiRespiratory Medicine CME
journal homepage: www.elsevier .com/locate/rmedcCase Report
Acute fatal amiodarone-induced lung toxicity after CABG surgery
Ioannis Panagiotou a, Michalis Doris b, Lazaros Karnesis c, Konstantina Tsakanika d, Charalampos Ladakis e,
Konstantinos Kanakakis a, Emmanouil Spiridakis a, Demosthenes Bouros f, Christophoros Kotoulas a,*
aCardiothoracic Surgery Department, “Iaso” General Hospital of Athens, Kiﬁssias Ave 38, 11526 Athens, Greece
bDepartment of Pulmonology, “Iaso” General Hospital of Athens, Kiﬁssias Ave 38, 11526 Athens, Greece
cDepartment of Internal Medicine, “Iaso” General Hospital of Athens, Kiﬁssias Ave 38, 11526 Athens, Greece
d Lavage Unit, “Sismanogleion” General Hospital of Athens, Kiﬁssias Ave 38, 11526 Athens, Greece
e Intensive Care Unit, “Iaso” General Hospital of Athens, Kiﬁssias Ave 38, 11526 Athens, Greece
fDepartment of Pulmonology, Democriteion University of Thrace, Greecea r t i c l e i n f o
Article history:
Received 22 April 2010
Accepted 13 May 2010
Keywords:
BAL (bronchoalveolar lavage)
Bypass coronary surgery
Arrhythmias
Respiratory failure
Pharmacology (lung)* Corresponding author. Tel.: þ30 210 7782220; fax
E-mail addresses: panagiotouioannis@yahoo.gr (I. Pa
com(M.Doris), karlaz12@yahoo.gr (L.Karnesis), n.tsakan
chladakis@mailbox.gr (C. Ladakis), k.kanakakis@
manospyridakis@in.gr (E. Spiridakis), bouros@med.
kotoulas.com (C. Kotoulas).
URL: http://www.kotoulas.com
1755-0017/$36.00  2010 Elsevier Ltd. All rights rese
doi:10.1016/j.rmedc.2010.05.003a b s t r a c t
Amiodarone is a commonly used anti-arrhythmic agent, with well-recognized chronic toxicity. Amio-
darone’s potential to cause acute lung damage even though less known can be occasionally severe or life
threatening. Herein, we report a case of a patient with fatal outcome who underwent coronary artery
bypass grafting and after a short course of therapy with amiodarone for postoperative ventricular
tachycardia developed acute amiodarone-induced pulmonary toxicity.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Amiodarone is a highly effective agent for the treatment of all
forms of supraventricular and ventricular arrhythmias, with
increasing use worldwide. Enthusiasm for this excellent agent has
been tempered by its well-recognized side effects. One of the most
serious side effects seen with amiodarone is pulmonary toxicity,
which is usually chronic, but seldom it can be acute or subacute, in
contrast with the general opinion that low cumulative dose therapy
is safe. Diagnosis of acute amiodarone toxicity is difﬁcult to establish
due to nonspeciﬁc symptoms, radiological ﬁndings and laboratory
data. The challenge of diagnosis is further compounded by the fact
that the latency from the onset of drug use to development of
toxicity can be high variable. Furthermore it seems that reaction to
amiodarone administration is idiopathic rather than dose-depen-
dent and risk factors that predispose individuals to the development
of acute pulmonary toxicity are not well characterized.: þ30 210 7772329.
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An 81-year-old Caucasian male with unstable angina was
admitted to the hospital for planned CABG surgery. He had
undergone a three-vessel coronary artery bypass grafting 13 years
ago and angioplasty on circumﬂex territory 3 years ago. Recent
angiography showed the SVG graft in LAD was sub-occluded. His
medical history included hypertension, diabetes mellitus, prostate
hypertrophy and hyperlipidemia. The admission chest X-ray ﬁlm
disclosed no abnormalities. Laboratory test results were within
normal limits.
The day after admission, the patient underwent CABG surgery
where LIMA anastomosed to LAD after laborious endarterectomy
and ligation of the existing SVG graft to the LAD. Six hours after
surgery when in the ICU the patient developed VT, he was deﬁb-
rillated once and after successful resuscitation amiodarone therapy
with intravenous loading (5 mg kg1) in 30 min was started.
Subsequently, a continuous 24-h intravenous infusion of amiodar-
one (900 mg/24 h) was instituted. The ﬁrst postoperative day the
patient was extubated. The second postoperative day IV amiodar-
one was stopped and started on 200 mg q.8h. pos. The third post-
operative day he was transferred to the ward and the 8th
postoperative day after a total dose of 5200 mg of amiodarone he
complained of lack of oxygen and he was treated with oxygen
therapy and diuresis with rapid improvement. Chest radiography
Fig. 2. Chest CT scan depicts bilateral densities with air-bronchogram and ground glass
opacities occupied both lungs and especially the lower lobes.
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day and after a total amiodarone dose of 6000 mg, he developed
thin dry nonproductive cough with normal breathing sounds on
auscultation while laboratory test results were also within normal
limits except for an increased CRP of 4.4. He started on a non-codein
antitussive and he was discharged on 12th postoperative day with
antibiotic therapy and amiodarone pos 200 mg q.d.
Four days later the patient was readmitted for low grade fever
(T¼ 37.4 C) and progressive nonproductive cough. A blood pres-
sure of about 100e60 mmHg and an oxygen saturation of 92% were
noted. Breathing sounds were decreased at the lung bases accom-
panied by bibasilar rales while the chest X-ray depicted bilateral
interstitial inﬁltrates especially in the right base (Fig. 1). Laboratory
workup was normal except for a CRP of 13.3. Transthoracic echo-
cardiogram showed no new wall motion abnormalities, preserved
ejection fraction, and no pericardial effusions. Amiodarone was
discontinued after a cumulative dose of 7200 mg (2400 mg iv and
4800 mg pos) given in 16 days. Blood culture was negative whilst
sputum culture grew enterococcus faecalis and the patient was
started on antibiotic therapy with ciproﬂoxacin and meropenem
but with no clinical improvement. Only after the addition of
hydrocortisone (40 mg q.8h IV) two days later, a temporal clinical
improvement was noted.
During the next three days there was progressive deterioration
of his clinical state, oxygen saturation continued to decline, inﬁl-
trates on chest X-ray occupied both lungs and fever remained
between 37.5 C and 38.0 C. Antibiotic therapy was changed to
meropenem, vancomycin and clarithromycin. On the 20th day the
patient was admitted to the ICU due to further deterioration of his
clinical state. He was tachypneic, tachycardic (Sat 91%, FiO2 80%)
and 6 h later he was intubated for respiratory failure (PO2
53.6 mmHg, PCO2 35.8 mmHg, pH 7.485, HCO3 26.4 mmol/L).
Serologic tests were negative for Mycoplasma pneumoniae, Chla-
mydia species and Legionella. PCR (polymerase chain reaction) of
sputum specimen for tuberculosis organisms were also negative as
was the PCR of pharyngeal swab for inﬂuenza A(H1N1)v virus. On
the 23th day a percutaneus tracheostomy was done. The next day
a high resolution computed tomography scan of the chest showed
bilateral densities with air-bronchogram and ground glass opacities
occupied both lungs and especially the lower lobes (Fig. 2).
The patient underwent ﬁberoptic bronchoscopy and diffuse
tracheobronchial inﬂammation was detected. The BAL specimen
was negative for hemorrhage, aspiration and malignancy but
indicative of inﬂammatory reaction. Therewas increased cellularity
with predominance of neutrophils. Moreover large alveolarFig. 1. Chest X-ray on 16th postoperative day (readmission day) shows bilateral
interstitial inﬁltrates especially in the right base.macrophages with foamy appearance (foamy cells) were present in
the ratio of 70%, a ﬁnding which is characteristic mainly of amio-
darone injury (Fig. 3). After that, the corticosteroid therapy was
changed to methylprednisolone 250mg q.6h IV. The respiratory
status only temporarily stabilized just to keep his sat. to the levels
of 92e94% with FiO2 90e100% for 3e4 days. Lung biopsy was not
done due to the critical status of the patient and the refusal of
patient’s relatives. From this point his respiratory status progres-
sively deteriorated. Despite our management he ﬁnally died from
severe respiratory failure on 44th postoperative day while the
function of the other organ systems remained substantially stable.
3. Discussion
In the presented case the clinical presentation including
progressive dyspnea, fever and nonproductive cough could mimic
acute pulmonary infection, congestive heart failure or pulmonary
embolism, all possible in the early postoperative period. The
patient’s symptoms were initially attributed to pulmonary infec-
tion and were treated accordingly. Symptoms started when the
cumulative dose of amiodarone was 5200 mg. This low cumulativeFig. 3. Bronchoalveolar lavage cytopreparation smear with marked foamy appearance
of alveolar macrophages characteristics of amiodarone.
I. Panagiotou et al. / Respiratory Medicine CME 4 (2011) 37e39 39dose made the possibility of amiodarone pulmonary toxicity to be
very low, thus only after initial failure of antibiotic treatment the
patient started on corticosteroid therapy.
Many authors support the use of a liberal steroid therapy in
patients inwhomunexplained progressive respiratory insufﬁciency
with bilateral parenchymal inﬁltrates develops after amiodarone
administration due to the highmortality rate of 50% among patients
with ARDS.1 The primary treatment is withdrawal of amiodarone
and provision of supportive care.2 Corticosteroid therapy can be life
saving for severe cases and for patients in whom withdrawal of
amiodarone is not advisable. Because of the drug’s accumulation in
fat tissues and its long elimination half life (approximately 45 days),
pulmonary toxicity may progress despite drug discontinuation;
furthermore it may recur upon steroid withdrawal.3 Due to the lack
of randomized trials on the proper steroid therapy the dose of given
steroids still depends on expert opinion and case reports.
It has been difﬁcult to predict which patients are at great risk for
the development of amiodarone pulmonary toxicity.4 Acute
pulmonary toxicity has been described after both cardiac and non-
cardiac operations and in patients who received or not preoperative
amiodarone therapy. Exposure to high levels of supplemental
oxygen may be a contributing factor while patients with preoper-
ative amiodarone administration for prolonged periods and those
with decreased diffusing lung capacity and older age are more
likely to develop acute pulmonary toxicity.5
The mechanisms of amiodarone pulmonary toxicity are not
completely understood. Many different pathways of toxicity have
been described including generation of toxic oxygen species,
immunological mechanisms, altering cellular gene expression and
direct toxic effects of amiodarone and its metabolite desethyl-
amiodarone (DEA).
The mortality rate is especially high in patients with underlying
lung disease and compromised pulmonary function and in those
with low ejection fraction explaining the higher incidence after
cardiac operations.6 This fact makes the need for early diagnosis
very important. Diagnosis is usually based on clinical and radio-
graphic ﬁndings and the exclusion of differential alternatives.Bronchoalveolar lavage may reveal lymphocytosis and abundant
alveolar macrophages with a foamy cytoplasm of undigested
phospholipids, which are found in all patients chronically exposed
to amiodarone. This fact is supportive but is not indicative of
pulmonary toxicity.7 Even though lung biopsymay be diagnostic, in
the presented case lung biopsy unfortunately was not possible.
Prompt recognition of amiodarone-induced lung disease, before
irreversible lung injury occurs, affords patients the greatest chance
of clinical and radiographic recovery. It seems that in some cases of
amiodarone-induced pulmonary injury, discontinuation of the
drug and steroid administration are not sufﬁcient for regression of
clinical symptoms.
The goal of the presented case is to reinforce the clinicians that
amiodarone-induced lung disease shouldn’t be excluded from the
differential diagnosis of acute postoperative respiratory failure
even after brief administration of the drug and even in patients
without predisposing factors. The high degree of suspicion is the
key to early diagnosis. We suggest that amiodarone, when neces-
sary in the early postoperative period for the treatment of cardiac
arrhythmias, should be given in the lower effective dose and for the
shortest possible period.References
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